Infectious Diseases

Our commitment to the fight against COVID-19

As a company with a long legacy of research in vaccines and infectious diseases, we’ve been committed to advancing an effective response to COVID-19 since it was first discovered.


Share this article


Covid-19 Header

«We’ve been focused on contributing our scientific expertise and experience to help address COVID-19.»


Our oral antiviral COVID-19 medicine

In collaboration with Ridgeback Biotherapeutics, we have advanced our research and development efforts for our COVID-19 medicine, making an important contribution to the care of COVID-19 patients.

We are working with health authorities to make our therapeutic option available worldwide.


Access to health care

We have a long track record of making our medicines and vaccines accessible and affordable. Our comprehensive supply and access strategy has enabled timely and broad access to our COVID-19 medicine for patients around the world, including in low- and middle-income countries. 

We have also provided UNICEF with up to 3 million treatment units for low- and middle-income countries.

Through our licensing agreements with generics manufacturers and the Medicines Patent Pool, more than 5 million courses of generic therapy have been delivered to 22 low- and middle-income countries through December 2022.


Our commitment as an employer

Throughout the COVID-19 pandemic, we’ve prioritized the health, safety and well-being of our employees and their families and supported our health care providers and our communities, including through volunteer work and donation efforts.

CH-NON-01216, 06/2023

Diversity and inclusion

Women at MSD

In the company’s more than 130-year history, many women have helped shape MSD.


Share this article


Women at MSD

We introduce eight remarkable women who have paved the way for future generations.


Ann Colon,

the first woman to celebrate 50 years with MSD.

Anna “Ann” Colon started in MSD’s packaging department in 1919. She became a manager in 1933.

When she retired after more than 50 years with MSD, she was the longest-tenured female employee in the company to date.


Grace Winterling,

the first female corporate officer at MSD.

Grace Winterling began her career during World War II in the Priorities Department before taking on supervisory roles in the Systems and Procedures, Organizational Planning, and Office Services Divisions.

In 1954, she became an administrative assistant to the Corporate Secretary. She was elected to Assistant Secretary in 1957 – a role that made her the first woman to become one of the companies corporate officers. The fact that a female executive had been named was so remarkable that it made headlines in local newspapers.

After 15 years in corporate leadership, Grace was named president of the company’s Foundation, which continues continues to fund qualified, eligible nonprofit and philanthropic organizations today. Grace retired in 1983 after 40 years with MSD.


Susan Jenkins,

the first african-american female chemist at MSD.

Susan R. Jenkins started at MSD Research Laboratories (MRL) in 1957 as one of the first African-American female chemists in the company, working on synthesizing enzymes, in addition to other activities.

She later moved to Human Resources, where she held various leadership positions, most recently as Senior Vice President of Human Resources.


Marian S. Heiskell,

MSD’s first woman elected to Board of Directors.

Marian S. Heiskell, Director of Special Activities at the New York Times Company, became the first woman elected to MSD’s Board of Directors in 1973.

She retained her seat on the Board for 18 years until she stepped down in 1991. Marian Heiskell was a well-known philanthropist and newspaper executive and died in 2019 at the age of 100.


Dorothy Bowers,

MSD’s first vice president of environmental and safety policy.

Dorothy Bowers joined MSD in 1974 as an engineer in the Environmental Department.

In 1982, she was promoted to Senior Director of Environmental Control. 10 years later, she was appointed to the newly created position of Vice President of Environmental and Safety Policy. Committed to ensuring our company was a leader in protecting the environment, Dorothy spearheaded numerous processes for reducing the company’s emissions and chemical releases, making MSD a model for the industry as one of the first companies to publicly commit to pollution reductions.

By 1999, after 25 years with the company, Dorothy had helped elevate environment protection to be among our highest business priorities before her retirement.


Christine Stubbs,

the first woman to earn a chemical engineering degree from Howard University.

Christine “Chris” Stubbs began working at MSD in 1983 as the first woman to earn an engineering degree from Howard University.

From then, she was one of the company’s most active employees in promoting equal opportunity. After 10 years with MSD, Chris managed materials logistics at the Flint River manufacturing facility in Albany, Georgia, where she supervised 31 employees. This alone was impressive, but it was her additional work promoting diversity that earned her recognition as one of the 1993 Black Engineers of the Year from US Black Engineer magazine.


Dr. Johnnetta B. Cole,

the first african-american female board member at MSD.

Dr. Cole joined the MSD Board of Directors in 1994 and retained the seat until 2009.

She was also the first African-American president of the prestigious Spelman College for African-American Women and also the first African-American woman on the Board of Directors at the Coca-Cola Company.

As early as 1997, Dr. Cole asserted that diversity was a smart investment for businesses, most notably stating, “Let’s address the question as to whether diversity in the American workforce is the right thing to do or the smart thing to do. The answer is: it is both.” 


Deborah Dagit,

MSD’s first Chief Diversity Officer.

Deborah Dagit worked as MSD’s first Diversity Officer for 12 years.

Deb, who had been instrumental in getting the 1990 Americans with Disabilities Act passed by Congress, helped our company tie diversity and inclusion initiatives directly to the company’s business practices and results. In 2010, she established MSD’s employee business resource groups (EBRGs) that are still active today. Deb retired from our company in December 2012.

We promote innovation through diversity and inclusion

Worldwide, MSD promotes a working environment with the aim of making people feel comfortable regardless of culture, age, sexual orientation or gender. Diversity and inclusion have been an integral part of the corporate culture for many years. This is also reflected in the numbers e.g., around 50% of those who fill management positions in Switzerland and worldwide are women.

MSD Women’s Network

In 1995, a group of female MSD employees in the USA got together to found the MSD Women’s Network. The network is committed to gender equity. It now has 57 chapters worldwide and over 9,000 members, both women and men.

In Switzerland, around 400 employees are involved with the MSD Women’s Network.

MSD as an employer

Would you like to work with us to further develop our medicines and healthcare solutions, to continuously improve medical care and to bring inspiration to new generations? Become part of our team!

To the MSD job portal

CH-NON-02261, 06/2023


Dr. Maurice Hilleman: “The father of modern vaccines”


Share this article


Vaccines are part of MSD’s history and are closely associated with Dr. Maurice Hilleman (1919-2005), the father of modern vaccine science. During his nearly 30-year career at MSD, he developed more than 40 vaccines for humans and animals. This legacy continues today thanks to our dedicated researchers.

The story of modern day vaccines began in 1796 when Dr. Edward Jenner inoculated 8-year-old James Phipps with cowpox as a way to protect him from smallpox. Jenner used the term “vaccination,” “vacca” being Latin for “cow.” In fact, it has been recognized for centuries that some diseases never reinfect a person after recovery. Smallpox was the first disease people tried to prevent by intentionally inoculating themselves with infected matter.

Dr. Edward Jenner inoculating 8-year-old James Phipps with cowpox.

Eight decades after Jenner published his findings, Louis Pasteur developed the first live attenuated bacterial vaccine. Attenuation is a process that weakens the bacteria or virus in a vaccine so it is less likely to cause disease, while still triggering an immune response similar to the natural infection. It would take many more decades for advances in basic and clinical research to make it possible for scientists to understand viruses well enough to begin developing vaccines that help protect against viral diseases.

primary article image


The scientists who made giant strides in the fight against viral diseases included Jonas Salk and Albert Sabin. Dr. Maurice Hilleman, who led MSD’s Department of Virus and Cell Biology from 1956 to 1984, also belonged to that distinguished group of vaccine pioneers. Credited with helping to develop more than forty vaccines, Dr. Hilleman’s passionate commitment continues to inspire scientists in medical research laboratories to this day.

Dr. Hilleman was born and raised on a farm in Montana. It was a hard life, but a farm background was a great foundation for his later work. “When you are brought up on a farm, you have a lot of general knowledge,” he said. After graduating from the University of Chicago with a doctorate in microbiology and chemistry, Hilleman chose to work at a pharmaceutical company instead of academia.

Despite his many accomplishments, including helping to develop more than 40 human and animal vaccines, Dr. Maurice Hilleman’s name is virtually unknown by the general public and press. Yet his impact on public health is undeniable.

"Since Pasteur, he's done more for preventive medicine than anyone else."

Dale C. Smith

Chief historian at the Uniformed Services University of the Health Sciences in Bethesda, MD

"His commitment was to make something useful and convert it to clinical use. Maurice's genius was in developing vaccines, reliably reproducing them, and he was in charge of all pharmaceutical facets from research to the marketplace."

Paul Offit

Chief of infectious diseases, Children's Hospital of Philadelphia and Hilleman's biographer

In 1988, President Ronald Reagan awarded the National Medal of Science to Dr. Hilleman, and in 1997, he was honored with The Albert B. Sabin Gold Medal Award. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases has called Dr. Hilleman one of the true giants of science, medicine and public health in the 20th century.

CH-NON-01259, 05/2023

Infectious Diseases

Addressing antibiotic resistance is more critical than ever. Here’s why.

Since their development, antibiotics have transformed health care and saved countless lives globally. But rising levels of antimicrobial resistance (AMR) make current antibiotics less effective.


Share this article


Doctor talking to patient lying in a hospital bed

There’s no single or simple solution to the complex problem of AMR, but we’re committed to investing our expertise and resources alongside our partners to get much-needed antibiotics to those who need them most. Lives are at risk, and the time to act is now.

True to our company’s longstanding tradition of preventing and treating infectious diseases, we’re proud to commit to invest $100 million over 10 years in the new AMR Action Fund. Through this groundbreaking partnership of leading pharmaceutical companies, philanthropies, development banks and multilateral organizations, we aim to bridge the gap between the innovative early antibiotic pipeline and patients. New antibiotics are urgently needed. With this new fund for antibiotic research and development, our collective aim is to bring two to four new antibiotics to patients and physicians by the end of the decade.

Here are five key reasons to build on these collaborative efforts to address AMR:


New antibiotics are urgently needed; however, there are relatively few in development.

AMR is a naturally occurring phenomenon through which bacteria build up defenses against antibiotics. The nature of resistance means that there is a continual need to develop new antibiotics so we can stay a step ahead of resistant pathogens.

MSD has remained committed to antibiotic R&D for over 80 years and brought forward new treatments each decade. However, major scientific, regulatory and economic challenges discourage innovation in antibiotics, resulting in a significant decline in the number of companies conducting antibiotic and antifungal R&D over the last two decades. Recognizing there is unlikely to be a one-size-fits-all solution to the problem, MSD and others have suggested a series of policy reforms across several regions of the world. However, time is running out. We need collaboration from policymakers across the globe to help antibiotic innovation flourish for decades to come.


Once new antibiotics are approved, they need to be used appropriately.

While developing new antimicrobials is important, slowing resistance to current medicines is equally crucial. Appropriate antibiotic therapy can play an important role in treating patients with resistant infections and preserving the effectiveness of antibiotics.

We must work together to implement evidence-based policies and programs that support the appropriate prescribing and use of antimicrobials. At MSD, we are making significant investments to support antimicrobial stewardship (AMS), helping hospitals around the world to develop and implement patient-centered AMS programs that are customized at the local level based on factors like epidemiology, clinical setting and resource availability. We also provide significant grant funding to support a wide range of AMS initiatives and collaborations.

Some of our global contributions to AMS:

Supported the development of several AMS Centers of Excellence throughout the world

Helped public health leaders effectively monitor and address emerging AMR infections, promote AMS and customize accepted AMS strategies to meet local needs

Contributed toward meaningful standardized patient safety outcome measures for US hospital AMS programs

Funded a round of Discovery Awards (small seed grants to help diagnostic innovators get their ideas off the ground and improve their chances of winning the UK-based Longitude Prize)


We must track resistance trends and use the data to inform on prescribing.

To ensure that antibiotics are being prescribed appropriately, clinical treatment guidelines must remain up-to-date and based on resistance trends. Surveillance studies can assist in identifying these trends in pathogen incidence and AMR, and can also identify emergent resistant strains.

At MSD, we work with public health bodies, health care professionals and diagnostics companies to inform appropriate antibiotic use by sharing surveillance data. One of the largest AMR surveillance programs, our Study for Monitoring Antimicrobial Resistance Trends (SMART) program has collected approximately 500,000 bacterial isolates from 217 sites in 63 countries since 2002. This data can help to curb the development of AMR by informing adequate treatment plans and prescribing guidelines that ensure antibiotics are used appropriately.


We need to think beyond human health.

The challenge of AMR is multifaceted, and we believe a One Health approach to creating policies is critical to attain optimal health for people, animals and our environment.

When it comes to animal health, vaccines should be considered a first line of defense against bacterial and viral diseases. By preventing diseases, vaccines can help minimize the need for antibiotics. MSD Animal Health is one of the largest manufacturers of animal health vaccines, supplying over 100B doses each year. We are also engaged in collaborative efforts to ensure new and existing antibiotics are effective now and in the future for all species.

Protecting the environment through responsible manufacturing is another key component of the One Health approach. To combat rising levels of antibiotics in the environment, we have committed over $100 million to ensure factory discharges do not present a risk to human health or the environment. We also worked with our partners in the AMR Industry Alliance to inform science‐based manufacturing targets to help ensure robust scrutiny of industry manufacturing supply chains.


The time to act against AMR is now.

We have received ample warning signs of the dangers of AMR. With collaboration across the scientific community and policymakers, it is preventable.

We all have a role to play as we look ahead to prepare for the next health crisis. We know that without action, AMR will have significant global consequences. We must act now to put measures in place to ensure we have the antibiotics we need for our generation and those to come.

CH-NON-01235, 05/2023

Our team

Walking the Talk: Lunch & Learn about HPV

Prevention starts with us! To mark International HPV Awareness Day, we met with gynecologist Dr. Alina Staikov for a Lunch & Learn. During the meeting, we had the opportunity to learn about the impact human papillomavirus (HPV) can have on our health and how we can protect ourselves and our loved ones from the viruses and certain cancers it causes.


Share this article


MSD employees at the Lunch & Learn about HPV with Dr. Alina Staikov

In celebration of International HPV Awareness Day on March 4, our Leadership Team invited all MSD employees to a Lunch & Learn with Dr. Alina Staikov. She is a gynecologist committed to the fight against cancer and is dedicated to education, treatment, prevention and early detection of the disease.

What does cancer have to do with HPV? Human papillomaviruses can cause cancer in some cases. The good thing is, if you are informed, you can protect yourself from HPV, prevent HPV-related cancers or get early treatment for them!

At MSD, we are committed to the prevention and early detection of cancer

As one of the leading pharmaceutical companies in oncology, we don’t just focus on educating the public – we live by what we say. This is why we regularly organize internal events to educate ourselves further on pertinent subjects – in this case about HPV and how it impacts health. More than 50 colleagues from all Swiss subsidiaries took the opportunity to learn from Dr. Staikov and ask their questions.

HPV can cause certain cancers

Dr. Staikov presented key facts about HPV. Among the other information she provided, she explained that these viruses are common and even teenagers should know about them, because even they can become infected. She explained that almost everyone will come into contact with HPV during their lifetime and what can happen if the virus does not go away on its own. This is the specific reason why Dr. Staikov focused on the options of early prevention and detection. After her lecture, we were afforded the opportunity to ask questions, making the event interactive and vibrant. What is the message we took away? Read the next section!

Five facts about HPV that everyone should know

  1. Human papillomavirus (HPV) is common and can occur in teenagers and adults.
  2. People are infected with HP viruses through person-to-person contact involving the skin and mucous membranes.
  3. HP viruses can cause certain cancers and precancerous tissue abnormalities.
  4. The most common HPV-related cancers include cervical cancer, anal cancer, and oral and pharyngeal cancers.
  5. Safer sex and vaccination can help prevent certain HPV-related diseases.      
Illustration HPV Virus

Getting the information to the people is the most important thing. If they are not informed, they can’t make decisions and they don’t have choices.“

Dr. Alina Staikov
Dr. Alina Staikov
The stage at the Lunch & Learn about HPV
At the event
MSD employees
Applause for Dr. Staikov

The event was a great opportunity for us to learn as a team and live by MSD culture.

Would you like to know more about HPV?

More information for parents, women, and men

Discover more

Want to know more about cervical cancer?

More information about the disease and treatment options

Information for women
Information for healthcare professionals

Mutter und Tochter laufen nebeneinander Arm in Arm

CH-NON-02171, 04/2023

Infectious Diseases

Our commitment to HIV treatments and prevention through the years

We continue to work at the forefront of the fight against HIV.


Share this article


HIV (human immunodeficiency virus) continues to be a major public health threat. The virus can lead to AIDS.

Since 1985, our company has been engaged in research and development (R&D) efforts in the prevention and treatment of HIV. Over the years, our scientists have made significant discoveries that changed the way HIV is treated.

Here are some historical moments highlighting this effort:

  • In 1982, the U.S. Centers for Disease Control and Prevention first used the term “AIDS,” or acquired immune deficiency syndrome, to describe the clinical syndrome caused by the human immunodeficiency virus (HIV). Julie Gerberding, chief patient officer, recalls: “I started my training at the University of California at San Francisco at the very beginning of the AIDS epidemic and took care of the earliest patients there who, in retrospect, we recognize had AIDS. It was a truly frightening disease. There were so many unknowns, including how it was transmitted.”
  • In the mid-1980s, MSD launched its HIV research program in response to what it perceived as a potential epidemic. Our scientists were among the first to discover and develop medicines for the treatment of HIV.
  • We were the first to publish the crystal structure of HIV protease, which is an enzyme which is essential for virus infectivity.
  • In 1992, MSD joined other pharmaceutical companies to create the Inter-Company Collaboration for AIDS Drug Development to research HIV treatments. By 1993, we were undertaking the biggest research program in our history, deploying more scientists to investigate AIDS than any other disease and testing tens of thousands of compounds.
  • The HIV/AIDS community continued to speak out for action. In 1995, Linda Distlerath, former executive director, Public Policy and MSD Research Laboratories Public Affairs, spent time reading letters sent from thousands of AIDS patients and activists urging MSD to produce a treatment for the disease quickly.
  • After years of study and development, MSD developed one of the first protease inhibitors. In 1995, prior to FDA approval, in conjunction with the U.S. Food and Drug Administration, patients and HIV advocacy groups, MSD offered a program that made its new HIV treatment available at no cost to selective patients before it was commercially available.
  • In 1996, the HIV treatment received FDA approval in a record-setting 42 days. It was an important early achievement in making HIV a survivable infection.
  • In 2012, The NAMES Project Foundation – with support from MSD – launched Call My Name national tour to bring attention to the distressing trajectory of the HIV epidemic in the Black communities in the U.S. The tour included creating new panels for the AIDS memorial quilt and educational workshops in 10 high-prevalence cities.
  • Daria Hazuda, VP, infectious disease discovery and chief scientific officer, MSD Exploratory Science Center has led the team working to identify new ways to attack and treat HIV.
  • In 2021, we entered into an agreement with Gilead to work together in the global HIV community in the fight against HIV.

CH-NON-01219, 05/2023


Things to know about cancer and the biomarker MSI-H/dMMR

Cancer patients need treatment that is most suitable for their specific disease. Biomarkers, biological characteristics that can be measured in blood or tissue samples, are an aid in finding the right treatment. MSI-h/dMMR is such a biomarker.


Share this article


Cancer is more than just one disease. There are many types of cancer and the disease can occur anywhere in the body. It develops when healthy cells grow uncontrolled: they become cancer cells and destroy healthy tissue. Cancer cells can spread, break away from their place of origin, and affect other parts of the body (metastasize). Cancer patients need treatment that is most suitable for their specific disease. Biomarkers, biological characteristics that can be measured in blood or tissue samples, are an aid in finding the right treatment. MSI-h/dMMR is such a biomarker.

Cancer is the second leading cause of death worldwide


In Switzerland, about 43’500 people are newly diagnosed with cancer each year, about 17’200 die of it, and about 67% still live 5 years after diagnosis.


In 2020, more than 19 million people worldwide were diagnosed with cancer. Nearly 10 million people died of it.

What happens in the body when cancer develops

All cells in our body have certain jobs to do. Normal cells divide in an orderly way. They die when they are worn out or damaged, and new cells take their place. In cancer, cells divide uncontrollably and crowd out the normal cells. This causes discomfort in the part of the body where the cancer started. Cancer cells can also spread to other parts of the body. Most cancers form lumps, which are also called tumors.

How do cancers differ?

Some cancers grow and spread fast. Others grow more slowly. They also respond to treatment in different ways. For example, some types of cancer can be treated well with surgery, while others respond better to drugs like chemotherapy, immunotherapy or a combination of different therapies. Often more than one treatment is used.

The role of biomarkers in cancer treatment

Biomarkers are certain biological characteristics that can be measured in blood or tissue samples. They help to better understand a cancer disease and can provide information for the choice of a treatment option. There are several biomarkers, MSI-H/dMMR is one of them.

  • MSI-H is the abbreviation for MicroSatellite Instability High. MSI is a change in short, repeating DNA sequences (microsatellites), that is often found in tumor cells of certain cancers. MSI-H cancer cells cannot correct errors that occur during DNA replication.
  • dMMR stands for “deficient mismatch repair”, which means “defective DNA repair system”. Normally, the DNA repair system intervenes when it identifies errors and repairs these cell changes. If this system does not work, it is called a defective DNA repair system (dMMR). A defective dMMR system can lead to microsatellite instability (MSI).

Tumors with high microsatellite instability often respond better to certain therapies. An MSI biomarker test can help to identify patients who may respond to such therapy.

How an MSI-H/dMMR biomarker test works

Every cancer is different. To help develop a treatment plan that is right for a patient, the doctor may order laboratory tests. These tests are used to evaluate the tumor for various biomarkers, including MSI-H/dMMR.

  • A tissue sample (biopsy) of the tumor is taken, and the doctor orders the test.
  • The doctor typically gets the results in 2 to 10 days.

Doctor and patient discuss treatment options based on the results and decide which treatment seems most appropriate.

CH-NON-00951, 12/2022

Hero Image
Our commitment

Pulmonary hypertension

Every single life motivates us, day after day, to give our best.

Pulmonary hypertension is a chronic disease that can be life-threatening if left untreated. At MSD, we are committed to people who are affected by this disease.

Pulmonary hypertension (PH) is a chronic disease characterised by increased blood pressure in the pulmonary circulation. It may lead to a significant impairment of physical capacity and can be life-threatening if left untreated. There are various treatment options that aim to alleviate symptoms, stop progression of the disease and maintain the highest possible quality of life.

Find out more

Our commitment in the area of pulmonary hypertension

For over

years committed to improving the lives of patients in Switzerland

In the year

introduction of the first soluble guanylate cyclase (sGC) stimulator for PH in Switzerland

Active since

in longstanding partnerships and projects

Our partnerships and projects

Collaboration with the Schweizerische Gesellschaft für Pulmonale Hypertonie [Swiss Society for Pulmonary Hypertension] (SGPH)

The SGPH is panel of experts that for more than 20 years has bundled all findings about pulmonary hypertension into one efficient network. We have supported the SGPH for years in different projects and initiatives.

Cooperation with patient organisations

We have been involved for years in collaborative partnerships with patient organisations and the Swiss PH Society for people with pulmonary hypertension.

Continuing education events and conferences

MSD regularly takes part in the conference of the Schweizerische Gesellschaft für Pneumologie [Swiss Society for Pulmonology] (SGP) and supports continuing education events for physicians in order to help clarify pulmonary hypertension and its treatment.

Clinical Research

For almost 130 years, we have conducted research worldwide to contribute to better health for our society with our medications and vaccines, for today and future generations. In Switzerland, MSD is currently conducting 42 clinical studies in different areas of therapy (as of 10/2023).

Find out more

Information and education

Especially in November, during Pulmonary Hypertension Awareness Month, and on 5 May, World Pulmonary Hypertension Day, we raise awareness of the disease and the importance of early detection among the general public.

frau lächelt in die kamera

"The sooner pulmonary hypertension is diagnosed and treated, the sooner a patient can benefit from an improvement in the quality of his or her life. With our commitment, we wish to contribute to the clarification and early detection of the disease".

Claudia Kimmich

Senior Customer Engagement Specialist Pulmonary Hypertension, MSD Schweiz

CH-NON-01417, 09/2023


MSD Switzerland awarded with the Swiss LGBTI Label

On June 16th 2021, MSD was awarded the with the Swiss LGBTI Label, a certification awarded to companies and organizations with an open and inclusive culture. This certification is intended to help promote the inclusion of LGBTI people at the workplace and beyond.


Share this article


LGBTI flag and logo

The Swiss LGBTI-Label is a seal of quality for organizations based in Switzerland, or Swiss organizations that work for the internal equality of LGBTI persons. LGBTI means persons who differ from the majority of the population in their sexual orientation or gender identity.

Diversity and Inclusion

At MSD Switzerland we believe that a diverse and inclusive workforce inspires innovation and is fundamental to our company’s success. While there has been great progress when it comes to LGBTQ+ rights, there is still work to be done — and we’re proud to play a role in achieving those goals. MSD has a longstanding tradition of supporting the LGBTQ+ community, in our company and beyond. Having an environment comprised of people from different dimensions of diversity also helps us better understand the unique needs of the customers, health care providers and patients we serve, including those with different abilities.

The Swiss LGBTI label executive board said:

“We congratulate MSD for receiving our Swiss LGBTI label. The label recognizes the exceptional work done by MSD to foster equality and inclusion of LGBTI People in the workplace. MSD went successfully through a very comprehensive assessment of the inclusiveness of its organizational practices. We applaud the very positive journey engaged by MSD, its contribution to societal positive change and its impact beyond its industry.”

Swiss LGBTI Label Logo

Until today, 18 companies and institutions were certified by the label, all based in German-speaking Switzerland. The Swiss LGBTI Label was developed by the business networks Network (Gay Leadership) and Wybernet (Gay Professional Women), with the help of the non-profit umbrella associations Transgender Network Switzerland, Pink Cross, LOS – Lesbenorganisation Schweiz and Regenbogenfamilien.

CH-NON-01248, 07/2021